Bio-Techne completes the sale of its subsidiary, Exosome Diagnostics.
Bio-Techne, a life sciences company, has announced the sale of its Exosome Diagnostics business to Mdxhealth SA. This move is part of Bio-Techne's strategic repositioning to focus on developing high-value, high-margin products and tools for the life science research and clinical diagnostics markets.
The transaction is valued at approximately $5 million in Mdxhealth stock, with additional future considerations. This sale is a significant reduction compared to the company's previous acquisition cost of Exosome Diagnostics, which was around $250 million in 2018.
The acquisition includes the ExoDx Prostate (EPI) test, a CLIA-certified clinical laboratory, and related assets. Mdxhealth plans to leverage these acquisitions to accelerate its leadership in the urology and prostate cancer diagnostic market.
Despite the sale, Bio-Techne will retain access to the proprietary exosome-based technology for ongoing kit development in its precision diagnostics segment. This means that the underlying technology will continue to be used beyond the divested business.
The upcoming Q4 preview for Bio-Techne indicates potential impacts from NIH funding cuts and tariffs. As of the press release, Bio-Techne's stock price stands at $53.96, down 1.24%.
TD Cowen has initiated a new buy for Bio-Techne based on its organic growth potential. The acquisition of Bio-Techne's Exosome Diagnostics business is expected to be completed during the first quarter of Bio-Techne's fiscal 2026.
[1] Bio-Techne Press Release [2] Mdxhealth Press Release [3] Bloomberg News
In summary, Bio-Techne's decision to sell its Exosome Diagnostics business is aimed at sharpening its focus on core, high-margin life science products and improving its operating margins. The future plans for the technology involve maintaining access to the proprietary exosome-based technology for kit development within Bio-Techne’s precision diagnostics growth pillar. The financial arrangement includes the sale to Mdxhealth for stock plus future payments, enabling Mdxhealth to lead in prostate cancer diagnostics while Bio-Techne reallocates resources.
Investing in high-value life science products and tools is now Bio-Techne's priority, as the company has sold its Exosome Diagnostics business to Mdxhealth SA for approximately $5 million in stocks, with additional future considerations. This strategic move in the business sector will enable Mdxhealth to take the lead in the urology and prostate cancer diagnostic market.
The securities division, TD Cowen, has expressed optimism for Bio-Techne's organic growth potential, initiating a new 'buy' for the company. Concurrently, the financial sector stands vigilant, monitoring potential impacts from NIH funding cuts and tariffs on Bio-Techne's operations.
